Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 24;15:261–275. doi: 10.2147/PGPM.S356326

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 Liu et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

DNTTIP2 overexpression promotes a malignant phenotype in glioma. (A) DNTTIP2 protein expression in normal human glioma cells. (B) The transfection efficiency was verified by the GFP expression as well as the Western blot. Transfection efficiency is represented as percentages. (C) Clone formation ability of the glioma cells transfected with the NC, sh- DNTTIP2, and oe‐DNTTIP2. (D) Cell scratch migration assay of the migratory ability of each group of glioma cells. (E) Cell invasion was determined via a Transwell assay. (F) Illustration of the model for Tube formation assay. (G) Tubule formation of HUVECs and column graph of tubule formation index in different groups. (H) Schematic diagram of subcutaneous tumor models. (I) Xenograft mouse tumors (n= 6 mice per group). (J and K) Volumes (J) of xenograft tumors measured twice a week and weights (K) of xenograft tumors at completion of the study. Data are means ± SEM *p < 0.05; **p <0.01; ***p < 0.001; ****p < 0.001.